Suppr超能文献

相似文献

1
Primary Hyperoxaluria Type 3 Can Also Result in Kidney Failure: A Case Report.
Am J Kidney Dis. 2022 Jan;79(1):125-128. doi: 10.1053/j.ajkd.2021.05.016. Epub 2021 Jul 7.
4
Primary hyperoxaluria type 1 in children: clinical and laboratory manifestations and outcome.
Pediatr Nephrol. 2023 Aug;38(8):2643-2648. doi: 10.1007/s00467-023-05917-x. Epub 2023 Mar 14.
5
Renal function can be impaired in children with primary hyperoxaluria type 3.
Pediatr Nephrol. 2015 Oct;30(10):1807-13. doi: 10.1007/s00467-015-3090-x. Epub 2015 May 14.
6
Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2.
Nephrol Dial Transplant. 2022 Apr 25;37(5):869-875. doi: 10.1093/ndt/gfab027.
7
HOGA1 Gene Mutations of Primary Hyperoxaluria Type 3 in Tunisian Patients.
J Clin Lab Anal. 2017 May;31(3). doi: 10.1002/jcla.22053. Epub 2016 Aug 26.
8
Late diagnosis of primary hyperoxaluria type III.
Ann Clin Biochem. 2017 May;54(3):406-411. doi: 10.1177/0004563216677101. Epub 2017 Jan 10.
9
Mutations in do Not Confer a Dominant Phenotype Manifesting as Kidney Stone Disease.
J Urol. 2021 May;205(5):1394-1399. doi: 10.1097/JU.0000000000001528. Epub 2020 Dec 22.
10
Metabolite diagnosis of primary hyperoxaluria type 3.
Pediatr Nephrol. 2018 Aug;33(8):1443-1446. doi: 10.1007/s00467-018-3967-6. Epub 2018 Apr 28.

引用本文的文献

1
Genotype and Phenotype Characteristics of Chinese Pediatric Patients with Primary Hyperoxaluria.
Hum Mutat. 2023 Sep 14;2023:4875680. doi: 10.1155/2023/4875680. eCollection 2023.
2
Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory.
Kidney Int Rep. 2024 Sep 1;9(11):3083-3096. doi: 10.1016/j.ekir.2024.08.031. eCollection 2024 Nov.
3
Primary hyperoxaluria type 3: from infancy to adulthood in a genetically unique cohort.
Pediatr Nephrol. 2025 Mar;40(3):731-741. doi: 10.1007/s00467-024-06536-w. Epub 2024 Oct 30.
5
Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin.
Pharmacol Rev. 2023 Dec 15;76(1):49-89. doi: 10.1124/pharmrev.123.000815.
6
Research progress on renal calculus associate with inborn error of metabolism.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023 Apr 25;52(2):169-177. doi: 10.3724/zdxbyxb-2022-0698.
7
Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).
Urolithiasis. 2023 Apr 28;51(1):80. doi: 10.1007/s00240-023-01453-3.
8
Characterization of Stone Events in Patients With Type 3 Primary Hyperoxaluria.
J Urol. 2023 Jun;209(6):1141-1150. doi: 10.1097/JU.0000000000003400. Epub 2023 Mar 8.
9
The retinal phenotype in primary hyperoxaluria type 2 and 3.
Pediatr Nephrol. 2023 May;38(5):1485-1490. doi: 10.1007/s00467-022-05765-1. Epub 2022 Oct 19.

本文引用的文献

1
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
N Engl J Med. 2021 Apr 1;384(13):1216-1226. doi: 10.1056/NEJMoa2021712.
2
Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2.
Nephrol Dial Transplant. 2022 Apr 25;37(5):869-875. doi: 10.1093/ndt/gfab027.
3
Pathophysiology and Treatment of Enteric Hyperoxaluria.
Clin J Am Soc Nephrol. 2021 Mar 8;16(3):487-495. doi: 10.2215/CJN.08000520. Epub 2020 Sep 8.
4
Investigational Therapies for Primary Hyperoxaluria.
Bioconjug Chem. 2020 Jul 15;31(7):1696-1707. doi: 10.1021/acs.bioconjchem.0c00268. Epub 2020 Jun 29.
5
Pyridoxine Responsiveness in a Type 1 Primary Hyperoxaluria Patient With a Rare (Atypical) Gene Mutation.
Kidney Int Rep. 2020 Apr 13;5(6):955-958. doi: 10.1016/j.ekir.2020.04.004. eCollection 2020 Jun.
6
Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up.
Kidney Int. 2019 Dec;96(6):1389-1399. doi: 10.1016/j.kint.2019.08.018. Epub 2019 Sep 3.
7
Metabolite diagnosis of primary hyperoxaluria type 3.
Pediatr Nephrol. 2018 Aug;33(8):1443-1446. doi: 10.1007/s00467-018-3967-6. Epub 2018 Apr 28.
8
Late diagnosis of primary hyperoxaluria type III.
Ann Clin Biochem. 2017 May;54(3):406-411. doi: 10.1177/0004563216677101. Epub 2017 Jan 10.
9
An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.
J Am Soc Nephrol. 2017 Feb;28(2):494-503. doi: 10.1681/ASN.2016030338. Epub 2016 Jul 18.
10
Renal function can be impaired in children with primary hyperoxaluria type 3.
Pediatr Nephrol. 2015 Oct;30(10):1807-13. doi: 10.1007/s00467-015-3090-x. Epub 2015 May 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验